Clinical Perspectives of Urocortin and Related Agents for the Treatment of Cardiovascular Disease

1Department of Molecular Cell Biology, Institute of DNA Medicine, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo 105-8461, Japan2Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 105-8461, Japan

Received 21 November 2011; Revised 7 February 2012; Accepted 7 February 2012

M. Perrin, C. Donaldson, R. Chen et al., “Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 7, pp. 2969–2973, 1995.View at Publisher · View at Google Scholar · View at Scopus

T. M. Reyes, K. Lewis, M. H. Perrin et al., “Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2843–2848, 2001.View at Publisher · View at Google Scholar · View at PubMed · View at Scopus

K. Lewis, C. Li, M. H. Perrin et al., “Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7570–7575, 2001.View at Publisher · View at Google Scholar · View at PubMed · View at Scopus